Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Hoffmann-La Roche
TCR2 Therapeutics
SOLTI Breast Cancer Research Group
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc